A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.
Also called NCT03656744
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 101 participants
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
- Registry
-
NCT03656744
-
- Other papers using this trial's data
- A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03656744. Randomized; quadruple masking; primary purpose treatment. Start 2018-11-26 (actual); primary completion 2020-02-07 (actual). Results posted on 2021-12-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
- Condition
- Fatty Liver, Nonalcoholic
- Condition
- NAFLD
- Condition
- Nonalcoholic Fatty Liver Disease
- Condition
- Nonalcoholic Steatohepatitis
- Condition
- Digestive System Diseases
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- HTD1801
- Intervention (Drug)
- Placebo
- Lead sponsor
- HighTide Therapeutics (Hong Kong) Limited
Record details
- Record id
cardio:ct-nct03656744- Content hash
c35b4151bf812e89cdd542ae51c977d3212919a57f14e07adbdb873d0b7c19ac